Search bioRxiv⌕ Search

Biology subjects

Cooper, C. R.

Publications and source records attributed to Cooper, C. R..

3 recordsLinked to original sources

Clonal interference and changing selective pressures shape the escape of SARS-CoV-2 from hundreds of antibodies

SARS-CoV-2 rapidly evolves to evade human immunity. While the viruss overall resistance to human polyclonal antibody responses has steadily increased over time, the dynamics by which it escaped individual monoclonal antibodies within these responses have not been thoroughly explored. Recently, a series of studies by Cao et al. [1, 2, 3] used deep mutational scanning (DMS) to identify which mutations allow the Wuhan-Hu-1 receptor-binding domain to escape binding by individual antibodies, doing so for thousands of antibodies. Here, we sought to use these data to retrospectively examine the evolutionary dynamics of escape from a set of 1,603 antibodies. For each antibody, we used the DMS data to predict an antibody-escape score for each of thousands of globally circulating viral sequences from the first 3.5 years of the pandemic, and then computed an escape trajectory that quantifies how the populations average escape score changed over time. We use pseudovirus neutralization data from Cao et al. and Wang et al. [4] to validate common patterns in escape trajectories. While some trajectories increase monotonically over time, others show large fluctuations as a result of clade-displacement events that reduce the frequency of antibody-escape mutations in the viral population. Fitness effects of mutations estimated from natural sequences suggest that the mutations are displaced due to clonal interference. Further, these estimates suggest that the order in which escape mutations arose is shaped by changing selective pressures. Overall, this work helps describe how SARS-CoV-2 evaded the individual components of a polyclonal immune response in nature, and suggests that evasion occurred via complex evolutionary dynamics.

microbiology↗

Computational Modeling and Analysis of the TGF-β-induced ERK and SMAD Pathways

TGF-{beta}, an important cytokine that plays a key role in many diseases regulates a wide array of cellular and physiologic processes via several TGF-{beta}-driven signaling cascades, including the SMAD and non-SMAD-driven pathways. However, the detailed mechanisms by which TGF-{beta} induces such diverse responses remain poorly understood. In particular, compared to the SMAD-dependent pathway, SMAD-independent pathways such as the ERK/MAPK pathway, which is critical in cancer progression, are less characterized. Here, we develop an integrated mechanistic model of the TGF-{beta}-triggered ERK activation pathway and its crosstalk with the SMAD pathway, an analysis of which demonstrates how SMAD dynamics can be significantly modulated and regulated by the ERK pathway. In particular, SMAD-mediated transcription can be altered and delayed due to expedited phosphorylation of the linker of SMAD by TGF-{beta}-activated ERK; and enhanced ERK activity, but attenuated SMAD activity, can be achieved simultaneously by fast turnover of TGF-{beta} receptors via lipid-rafts. Also, in silico mutations of the TGF-{beta} pathways reveal that the dynamic characteristics of both SMAD and ERK signaling may change significantly during cancer development. Specifically, normal cells may exhibit enhanced and sustained SMAD signaling with transient ERK activation, whereas cancerous cells may produce elevated and prolonged ERK signaling with enervated SMAD activation. These distinctive differences between normal and cancerous signaling behavior provide clues concerning, and potential explanations for, the seemingly contradictory roles played by TGF-{beta} during cancer progression. We demonstrate how crosstalk among various branch pathways of TGF-{beta} can influence overall cellular behavior. Based on model analysis, we hypothesize that aberrant molecular alterations drive changes in the intensity and duration of SMAD and ERK signaling during cancer progression and ultimately lead to an imbalance between the SMAD and ERK pathways in favor of tumor promotion. Thus, to treat cancer patients with a genetic signature of oncogenic Ras effectively may require at least a combination therapy to restore both the expression of TGF-{beta} receptors and the GTPase activity of Ras.

systems biology↗

In Vitro Assessment of Efficacy and Cytotoxicity of Prunus africana Extracts on Prostate Cancer C4-2 Cells

Phenolic compounds are products of secondary plant metabolism known for their biological activity including their antimicrobial, antioxidant, analgesic, stimulant, anti- carcinogenic, and aphrodisiac properties. The main objective of this study was to assess the potency/cytotoxic effects of Prunus africana extracts on prostate cancer cells in vitro. Using different concentrations of P. africana extracts, prostate cancer C4-2 cells, a hormonally insensitive subline of LNCaP cells, were treated in a proliferation assay. A concentration dependent inhibition of cell growth in cells treated with P. africana bark and root extracts was present from days 1 through 3 of incubation, with the methanol extract of the bark showing the strongest effect. Compared to other plant parts, leaf extracts were significantly less cytotoxic at the same concentrations. As C4-2 cells are hormonally insensitive and designed to mimic advanced prostate cancer, crude extracts of P. africana are a possible treatment option, not only for hormone sensitive prostate cancer, but also advanced, hormonally insensitive prostate cancer.

cancer biology↗